Novavax s COVID Vaccine Found Effective in Final Trial Analysis by Angela Mohan on March 12, 2021 at 2:31 PM
Novavax s COVID-19 shot found to be 96.4% effective against mild, moderate and severe symptoms of COVID-19 in the final analysis of a late-stage trial in the U.K.
The vaccine would be produced at eight locations including the Serum Institute of India, with which Novavax has an agreement to produce around 2 billion doses a year.
The analysis showed the vaccine had 86.3 percent efficacy against the UK variant B.1.1.7/501Y.V1 but it was only 55.4 percent against the South African variant B1.351 among the HIV-negative trial participants, the company said.
March 12, 2021 6:08 AM By Brandon Lee
President Joe Biden offered Americans a glimpse of hope that life would begin to return to normal this summer as he marked a year of U.S. shutdowns and death, ordering a further acceleration of the governmentâs efforts to end the pandemic.
In his first prime-time address to the country since his inauguration, the president directed states to make all U.S. adults eligible for vaccinations by May 1, and he said his administration would reach his goal of 100 million shots in his first 100 days in office by his 60th day as president.
âWeâre not only going to meet that goal, weâre going to beat that goal,â he said in remarks on the anniversary of the day a year ago when the World Health Organization declared a pandemic. âI need you to get vaccinated when itâs your turn and you can find an opportunity,â Biden said.
Приключения норвежского авантюриста в Алматы pda.kp.kz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pda.kp.kz Daily Mail and Mail on Sunday newspapers.
Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose.Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints. MALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy of 81%. “We are thrilled with the interim
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021
No safety issues identified, consistent with observations in previous IDMC reviews
Lyon (France) and Cambridge, MA (U.S.), February 8, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that TRYbeCA-1, a Phase 3 clinical trial evaluating eryaspase in second-line pancrea